PeriVision

👁️ Visual field testing (VFT): A challenge for patients & clinics alike. While VFTs are crucial diagnostic tools to detect and monitor glaucoma and other neuro-ophthalmic conditions, traditional VFTs demand intense patient focus, specialised equipment, and hospital resources like trained staff and dedicated rooms. This creates bottlenecks and makes it hard to meet the growing demand for glaucoma care. Learn more directly from leading ophthalmologist Prof. Marion Munk, M.D., Ph.D in the video below. 🥽 PeriVision is re-imagining this clinical workflow. Our VisionOne eye testing platform: - reduces test time by up to 70% with our patented SORS algorithm - automates test monitoring with a virtual assistant, saving 60-70% assistant time - allows testing on a portable & ergonomic headset with 8.75 / 10 self-reported comfort score by patients. 🌐 For more information about PeriVision, VisionOne or our research, please visit https://lnkd.in/dViWVePf or contact info@perivision.com . #ophthalmology #optometry #eyecare #glaucoma #innovation #medtech #healthtech #AI #VR #tech

💡 We introduce a new section in our newsletter & LinkedIn page this year: the scientific spotlight to discuss fascinating ophthalmology research. Today, we look at the inroads of generative AI into glaucoma diagnosis. 📑 Scientific spotlight: “The Use of ChatGPT to Assist in Diagnosing Glaucoma Based on Clinical Case Reports" (Source: Delsoz, M., Raja, H., Madadi, Y. et al., Ophthalmol Ther 12, 3121–3132 (2023). https://lnkd.in/dS7emS34) 🔎 RESULTS | The study explored the potential of ChatGPT to diagnose glaucoma using clinical case reports. The AI was given 11 textual case reports and achieved a 72.7% accuracy, comparable to the 3 residents, even outperforming 1. It was correct on 8 out of 8 cases with common glaucoma cases, but incorrect on uncommon / atypical cases. While ChatGPT showed strong reasoning abilities, its performance was hindered by the lack of access to crucial clinical data, e.g. fundus images or visual field tests (VFT). This limitation prevented the AI from matching the nuanced, case-specific insights provided by the residents with access to this data. ➡️ INSIGHT | The study highlights both the potential and challenges of AI in ophthalmology. Integrating multi-modal data like treatment records, VFTs or imaging will be essential to enhance accuracy. Without diverse and representative data, AI will not achieve its full potential. This means collaboration between AI engineers and clinicians is crucial. At PeriVision, we partner with eye clinics like Insel Gruppe to build such comprehensive datasets capturing the broad spectrum of patient demographics and disease presentations. This collaborative, user-centric approach enabled us to reveal various unmet needs and leverage clinical data to develop algorithms addressing real-world challenges like SORS (fast & reliable visual fields for glaucoma), FIPR (fixation-independent perimetry for retina diseases) or OphthaPro (AI portfolio for progression detection & prediction). 🌐 For more information about PeriVision and our research, please visit https://lnkd.in/dViWVePf or contact info@perivision.com . [Image credit to Mistral AI: futuristic AI-based progression analysis seems to be a very different thing, but there is still pen & paper🙃] #ophthalmology #optometry #eyecare #glaucoma #innovation #medtech #healthtech #AI #VR #tech

👁️ Yesterday, we invited Swiss eye doctors in the Romandie region to Biopôle Lausanne together with Roche Switzerland and VON HOFF AG to provide an outlook into the future of ophthalmology with a focus on innovative diagnostics, new therapeutics and changes in Swiss healthcare policy (TARDOC). 💡 CTO Dr. Şerife Seda Kucur Ergünay and CMO Dr. Kevin Gillmann • MD PhD MBBS MBA FEBO MArch PgCert (HMS) showcased our AI- & VR-eye testing platform VisionOne. They also shared results form our latest research on AI glaucoma progression prediction and optimized perimetry in retina diseases, in partnership with Insel Gruppe and the ARTORG Center for Biomedical Engineering Research / University of Bern. On top, Adil EL Maftouhi from the Centre ophtalmologique de Rive , Genève shared exciting (and incredibly aesthetic) insights into the latest OCT imaging advances with Intalight. 📨 If you missed the event, visit our website https://lnkd.in/dViWVePf or contact us here on LinkedIn or at info@perivision.com to learn more about our product and research. #ophthalmology #optometry #eyecare #glaucoma #innovation #medtech #healthtech #AI #VR #tech

💡 Apart from the usual R&D, commercial and regulatory highlights we will introduce 2 new sections in our newsletter and LinkedIn page this year: team and scientific spotlights. In these sections, we will introduce the people behind PeriVision and fascinating ophthalmology research. Today, we start off with co-founder and CTO Dr. Şerife Seda Kucur Ergünay .   🥼 Professional background Serife holds a BSc. in Telecommunication Engineering from Istanbul Technical University, a MSc. in Information & Communication Technologies from EPFL. She then obtained a PhD. in Biomedical Engineering from the University of Bern. During more than six years of research, she focused on applying AI to ophthalmology and perimetry data, closely working with the eye clinic in Bern. For her translational research she was granted a BRIDGE proof-of-concept grant by the Swiss National Science Foundation SNSF (SNCF). Her patents and papers form the foundation of PeriVision’s IP and platform.   🧩 How does your role contribute to Perivision’s mission of revolutionising eye care? As CTO, I lead our product development and work closely with our Chief Medical Officer Kevin Gillmann • MD PhD MBBS MBA FEBO MArch PgCert (HMS) and clinical partners like Insel Gruppe to build our product in line with their needs. It is an exciting and challenging role, because we work with a multitude of advancing technologies and our users have very high expectations.   💟 What appealed to you about founding a company? I very much like the idea of creating something from scratch that in the end touches peoples’ lives. It is not easy and involves a lot of juggling when raising a family at the same time. But the goal of saving people’s eyesight gives me the motivation to overcome any setbacks along the way.   ➡️ Read a full interview with Serife under the following link or hear her present about our product and research on Thursday evening at Biopôle Lausanne for an exclusive event together with Roche & VON HOFF AG (more info via info@perivision.com or LinkedIn): https://lnkd.in/dK8Bz2T4   #ophthalmology #optometry #eyecare #glaucoma #innovation #medtech #healthtech #AI #VR #tech

🚀 Five companies were supported by the Biopôle Start-up Fund in 2024. ➡️ Impli joined the programme and secured its first year of funding ➡️ Emovo Care, Neuria SA and PeriVision all received a second year of financial support ➡️ biped.ai was given funding for a third and final year 💰The Biopôle Start-up Fund offers early-stage companies up to CHF 90,000 and prepares its entrepreneurs to present to future investors via its affiliated Investment Readiness Programme. 👉 Learn more about the fund and last year's recipients here: https://lnkd.in/dzH9x53j Photo credit: Emovo Care device – Tania Emery

📢 EVENT ALERT: PeriVision will co-host an exclusive event together with Roche Switzerland and VON HOFF AG, our Swiss distribution partner, at Biopôle Lausanne on Feb 13, 2024. The aim is to bring together eye doctors in Switzerland and provide an insightful outlook into the future ophthalmology in terms of diagnostics, therapeutics and Swiss healthcare policy. 💡 As part of the high-calibre program, CTO Dr. Şerife Seda Kucur Ergünay and CMO Dr. Kevin Gillmann • MD PhD MBBS MBA FEBO MArch PgCert (HMS) will present our eye testing platform VisionOne as well as our most recent research on AI glaucoma prognostics and optimized perimetry in retina diseases in collaboration with Insel Gruppe and the ARTORG Center for Biomedical Engineering Research / University of Bern. Attendees will obtain 2 educational credits. 📨 Contact us here on LinkedIn or under info@perivision.com for further information or to attend the event. #ophthalmology #optometry #eyecare #glaucoma #innovation #medtech #healthtech #AI #VR #tech

🙏 Thanks Ernest Cavin for this insightful summary of our Innosuisse-funded research on AI glaucoma progression prediction by Marta Colmenar from the ARTORG Center for Biomedical Engineering Research / University of Bern under Raphael Sznitman's guidance. ❓ Why does it matter? Glaucoma continues to be one of the leading causes of irreversible blindness worldwide. The need for early detection and precise monitoring has never been more critical. More accurate detection and anticipation of disease progression allows to stratify patients better and personalize treatment pathways. 🧠 How did we do it? The team leveraged advanced non-linear machine learning models such as AdaBoost and autoencoders and then compared against traditional linear models. 🏆 What was the result? The results speak for themselves: non-linear methods consistently demonstrated better predictive accuracy and captured more nuanced progression patterns. For stage classification, the AdaBoost model achieved kappa metrics as high as 0.86, while for forecasting entire visual fields (VFs), the auto-encoder achieved mean absolute error (MAE) values as low as 2.41, significantly outperforming linear regression models. ➡️ What's next? By integrating the latest advancements in AI, we are moving closer to a future where glaucoma care is more personalized and precise. With our AI solutions we aim to provide clinicians with more confidence when staging glaucoma or assessing progression risk, enable earlier interventions and ultimately scale access across diverse clinical settings and patient demographics. Stay tuned for more! 🌐 For more information about PeriVision, VisionOne or partnership opportunities, please visit www.perivision.com or contact info@perivision.com. #ophthalmology #optometry #eyecare #glaucoma #innovation #medtech #healthtech #AI #VR #tech

🚀𝗦𝗢𝗥𝗦: 𝗔 𝗚𝗮𝗺𝗲 𝗖𝗵𝗮𝗻𝗴𝗲𝗿 𝗶𝗻 𝗣𝗲𝗿𝗶𝗺𝗲𝘁𝗿𝘆!🩺 The 𝗦𝗲𝗾𝘂𝗲𝗻𝘁𝗶𝗮𝗹𝗹𝘆 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗲𝗱 𝗥𝗲𝗰𝗼𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 (𝗦𝗢𝗥𝗦) is a groundbreaking innovation that is revolutionizing visual field testing. 🌟 Why SORS? SORS combines efficiency and precision like no other strategy, offering clear advantages: ✅ 𝗙𝗮𝘀𝘁𝗲𝗿: Up to 34% shorter test times through intelligent selection of test locations. ✅ 𝗠𝗼𝗿𝗲 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲: High diagnostic accuracy, even for complex visual field defects. ✅𝗣𝗮𝘁𝗶𝗲𝗻𝘁-𝗳𝗿𝗶𝗲𝗻𝗱𝗹𝘆: Shorter and more efficient tests mean less strain on patients. Compared to established methods like SITA (ZEISS Group) and TOP (Haag-Streit), SORS not only saves significant time but also delivers outstanding results – a critical competitive advantage for our VisionOne™ platform. 📄𝗔 𝗯𝗶𝗴 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝘁𝗵𝗲 𝗮𝘂𝘁𝗵𝗼𝗿𝘀! This groundbreaking concept was developed by leading experts Şerife Seda Kucur Ergünay and Raphael Sznitman. Their contribution has been instrumental in advancing the field of perimetry and a true game changer in ophthalmology! You can find the further documents here: https://lnkd.in/d6dQERdc 🎯 Our vision at PeriVision: With SORS, we are setting new benchmarks in glaucoma diagnostics, enabling clinicians to make better decisions and provide optimal care for their patients. Insel Gruppe University of Bern NHS England #SORS #Innovation #VisionOne #Ophthalmology #GlaucomaDiagnostics #HealthcareTechnology #GameChanger

🏆 𝗖𝗮𝗻 𝗬𝗼𝘂 𝗧𝗼𝗽 𝗧𝗵𝗲 𝗟𝗲𝗮𝗱𝗲𝗿𝗯𝗼𝗮𝗿𝗱? Do you have what it takes to beat PeriVision's high score of 𝟰𝟵.𝟳𝟱? 🕸️ Show us how your startup measures up and take it to the next level! 🚀 📅 Applications to 𝘀𝗲𝗰𝘂𝗿𝗲 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 for your HealthTech startup are open until the 𝟮𝟯𝗿𝗱 𝗼𝗳 𝗝𝗮𝗻𝘂𝗮𝗿𝘆. Don’t miss this opportunity to pitch at our 𝗼𝗻𝗹𝗶𝗻𝗲 𝗲𝘃𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝟭𝟯𝘁𝗵 𝗼𝗳 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆! 🔍 𝗪𝗵𝗮𝘁 𝗪𝗲’𝗿𝗲 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗙𝗼𝗿: - Strong Team Dynamics - Proven Traction in the Market - High Market Attractiveness - Competitive Advantage - Robust Support Network - Clear Fundability Take this chance to gain exposure, receive valuable expert feedback, and showcase your strengths in HealthTech innovation! 👉 𝗔𝗽𝗽𝗹𝘆 𝗻𝗼𝘄 and join our HealthTech portfolio: https://lnkd.in/eRqa9A32

𝗜𝗻𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗱𝗮𝘆 𝗼𝗳 𝗻𝗲𝘁𝘄𝗼𝗿𝗸𝗶𝗻𝗴! Today, representatives from over 60 Swiss Academic Institutions and Organizations in the Innovation Ecosystem gathered in Biel/Bienne for the 1st Swiss Academic Innovation and Entrepreneurship Forum (#SAIEF). One of the key goals of the new forum is to bring practitioners and relevant stakeholders from across Switzerland together for a structured discussion on how to best foster innovation and entrepreneurship at Swiss academic institutions. A special thank you goes to keynote speaker Arno Meerman, CEO of the University Industry Innovation Network (UIIN), and our panelists: Jaisli Eva, President of the Board of Directors, bpswisstools Patrick Kessel, CEO, PeriVision Christian Brunner, Head, BRIDGE Funding Programme The 1st SAEIF was a completely community-driven initiative and would not have been possible without the dedicated support of the members of the Organizing committee: Sébastien Hug, Eliav Haskal, LORENZ PROBST, Anita Buchli, Anna Gromova, Maria Håkanson, Maria-Luisa Fuchs, Maria Friedrich, Philipp Bubenzer, Maurizio Caon, Maurice Gaillard, Julien Levallois, Samuele Morales We’re humbled by the positive response, lively discussion and positive feedback on the forum. We thank the whole community for making the forum a success. This event is just the beginning of an exciting journey for Swiss universities to strengthen exchange and knowledge transfer around academic innovation and entrepreneurship support. #Innovation #Entrepreneurship #SwissAcademia #Collaboration #SAIEF Swiss Center for Design and Health AG BRIDGE Funding Programme Bern Economic Development Agency Swissnex Venturelab Arno Ratzinger, Eliane Gisler, Benjamin Herbst, Elsa Callini, Stefanie Dobitz, Jennifer Berger, Lan [Lê Diêm] Tran